So far, at least 30 clinical trials have been completed or are underway for ovarian cancers using the monotherapeutic anti–PD-1 antibody pembrolizumab (response rate [RR] 10%, n = 104) [63], the anti–PD-L1 antibody avelumab (RR 10%, n = 104) [64], or combinations of these agents with conventional cancer therapies (CTG). This evidence concerns the gene PDCD1 and ovarian cancer.